Curis to Release Third Quarter 2007 Financial Results and Hold Conference Call on October 30, 2007.CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will release its third quarter financial results on Tuesday, October 30, 2007 before the market opens. The Company will also hold a conference call on October 30, 2007 at 10:00 a.m. Eastern time to discuss its financial results, the progress of CUDC-101 and other multi-target inhibitors that Curis is developing under its Targeted Cancer Drug Development Platform, Curis' Hedgehog-based product development programs under collaboration Working together on a project. See collaborative software. with Genentech and Wyeth, as well as additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call. To access the live conference call, please call (800) 329-9097 from the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. or Canada or (617) 614-4929 from other locations, shortly before 10:00 a.m. Eastern time. The conference ID number is 30281225. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 p.m., Tuesday, November 13, 2007. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 48805608. About Curis, Inc. Curis is a drug development company that is committed to leveraging its innovative signaling pathway pathway /path·way/ (path´wa) 1. a course usually followed. 2. the nerve structures through which an impulse passes between groups of nerve cells or between the central nervous system and an organ or muscle. drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease Noun 1. neurological disease - a disorder of the nervous system nervous disorder, neurological disorder disorder, upset - a physical condition in which there is a disturbance of normal functioning; "the doctor prescribed some medicine for the disorder"; and cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . For more information, visit www.curis.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion